India’s Contract Manufacturing: Prospects And Pains
This article was originally published in PharmAsia News
Is the general uptrend in India's contract manufacturing segment sustainable, despite some sentiment-dampening run-ins with regulators over compliance concerns?
You may also be interested in...
SaNOtize is in partnering talks with large firms in India to manufacture and distribute its nitric oxide nasal spray for COVID-19. The Canadian company believes the product, which already has an interim approval in Israel, could potentially reduce viral load of SARS-CoV-2 variants, as well as influenza and other respiratory viruses.
UK studies indicate the potential of inhaled budesonide in improving COVID-19 recovery time in specific groups, with some leading Indian physicians suggesting that the widely available asthma/COPD therapy should be selectively evaluated in the Indian context as well.
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.